Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06593600 · ClinicalTrials.gov registry record · Phase 2
Study of Natriuretic Peptide Receptor 1 (NPR1) Antagonist in Adult Patients With Postural Orthostatic Tachycardia Syndrome (POTS)
A Phase 2 study of Postural Orthostatic Tachycardia Syndrome (POTS), sponsored by Regeneron Pharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 81
- Enrollment target
- 18
- Study locations
NCT06593600 is a Phase 2 study of Postural Orthostatic Tachycardia Syndrome (POTS) that is actively recruiting participants, run by Regeneron Pharmaceuticals. The registered enrollment target is 81 participants, below the 90-participant average among 4 other Postural Orthostatic Tachycardia Syndrome (POTS) trials with a reported enrollment target (10% lower). The trial reports 18 study locations across 14 states.
The verdict
NCT06593600, a Phase 2 study of Postural Orthostatic Tachycardia Syndrome (POTS), is actively recruiting participants, sponsored by Regeneron Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 81 participants
- Enrollment target
- 18
- Study locations
Study Summary
This study is researching an experimental drug called REGN7544 (called "study drug"). The study is focused on participants with POTS. The aim of the study is to see how safe, tolerable, and effective the study drug is. The study is looking at several other research questions, including: * How the study drug changes heart rate and blood pressure in participants with POTS * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)
Conditions Studied
Interventions
- DRUG Placebo
- DRUG REGN7544
Study Locations (18)
California
- North County Neurology Associates - Carlsbad
- Stanford University - Palo Alto
- Southern California Heart Specialists - Pasadena
New York
- New York University Langone - New York
- Columbia University - New York
Alberta
- University of Calgary - Calgary
- University of Alberta Hospital - Edmonton
Arizona
- Mercy Gilbert Medical Center - Gilbert
Connecticut
- Yale University - New Haven
Florida
- Innovative Research of West Florida, Inc. - Clearwater
Indiana
- Indiana University Health Neuroscience Center - Indianapolis
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2024-11-13 |
| Est. Completion | 2026-06-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06593600
The ClinicalTrials.gov registry entry for NCT06593600 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 81 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 90-participant average among 4 other Postural Orthostatic Tachycardia Syndrome (POTS) trials with a reported enrollment target (10% lower). The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Postural Orthostatic Tachycardia Syndrome (POTS) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06593600 reports 18 study locations spanning 14 distinct geographic areas - top geographies include California, New York, Alberta.
Frequently Asked Questions
What is clinical trial NCT06593600 about?
NCT06593600 is a clinical study titled "Study of Natriuretic Peptide Receptor 1 (NPR1) Antagonist in Adult Patients With Postural Orthostatic Tachycardia Syndrome (POTS)". This study is researching an experimental drug called REGN7544 (called "study drug"). The study is focused on participants with POTS. The aim of the study is to see how safe, tolerable, and effective the study drug is. The study is looking at several other research questions, including: * How the...
What is the current status of trial NCT06593600?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 81 participants. The study started on 2024-11-13. Estimated completion is 2026-06-11.
What conditions does trial NCT06593600 study?
This clinical trial studies the following conditions: Postural Orthostatic Tachycardia Syndrome (POTS).
What interventions are being tested in trial NCT06593600?
The interventions under investigation include: Placebo (DRUG), REGN7544 (DRUG).
Who is sponsoring clinical trial NCT06593600?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06593600 being conducted?
This trial has 18 study locations across Arizona, California, Connecticut, Florida, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Postural Orthostatic Tachycardia Syndrome (POTS)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Programming Aquatic Therapy for POTS
RECRUITING · NA
-
Long COVID-19 Cutaneous Signatures: An ARPA Funded Research Project
ACTIVE NOT RECRUITING
-
Abdominal and Lower Extremity Compression During Tilt Table Testing in Adolescent POTS Patients
COMPLETED · NA
-
The Renin-Aldosterone Axis in Postural Tachycardia Syndrome
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.